AMYPAD Confirms: Amyloid PET Improves Diagnosis
In a large European study, the scans changed the diagnosis in a third of cases. They boosted the doctor's confidence in making the call, and predicted cognitive decline.
ALL NEWS
6400 RESULTS
Sort By:
- Most Recent
- Most Commented
In Brain With Christchurch Mutation, More ApoE3 Means Fewer Tangles
The autopsy of a woman with a the PSEN1 Paisa mutation plus a homozygous ApoE3 variant showed an unusual distribution of tau tangles. Gene-expression studies pinpointed vulnerable neurons that were spared, and riled-up microglia in tangle-ridden zones.
Head-to-Head Study Confirms Plasma p-Tau231 Rises First in Early AD
Plasma p-tau217 and p-tau181 better track amyloid PET, tangles, and subtle cognitive decline.
A Chat Every Other Day Keeps Dementia at Bay?
The I-CONECT trial found that regular video chats boosted cognition in socially isolated older people. Even a weekly phone call enhanced their feelings of social connectedness.
Lifestyle Interventions May Fend Off Decline; Social Contact Helps
In “Maintain Your Brain,” virtual interventions gave participants a memory boost. In EXERT, cognition held steady in people who exercised. Both groups were coached.
Bringing Aduhelm—and Antibodies to Come—Into Practice
Scientists are refining safety and biomarker disclosure protocols, and are preparing to collect data on how well the new drugs work.
Could Benefit of Plaque Removal Grow in Time?
A mathematical model predicts that a tiny difference in CDR-SB after two years of treatment would grow fivefold over the next three years as progression curves separate.
Rare Variants Net New Alzheimer’s Gene, Links Between AD and CAA
Rare AD risk variants cluster within TREM2, SORL1, and the newcomer EXOC3L4. Rare mutations in ABCA7 associate with cerebral amyloid angiopathy.
Blood Tests: Charting the Path to Primary Care
Certain blood biomarker tests can tell that amyloid has built up in a person's brain and that their thinking will decline. What are the challenges ahead before these tests can be rolled out to medical care settings everywhere?
Blood Tests Go Head-to-Head in Community Cohorts
A cast of blood biomarkers for Alzheimer's has emerged from studies in research cohorts, and is now being put to the test in community cohorts. At AAIC, direct comparisons of top contenders showed that some detect amyloid and impending cognitive decline.
Alzheimer's Blood Tests Have Arrived; Road to Broad Use Still Stretches On
Finally, blood biomarkers for AD are here. Alas, the path to routine use is fraught. At AAIC, scientists discussed new guidelines, head-to-head comparisons, and logistical, technical, and ethical hurdles ahead.
High-Res Spatial Transcriptomics Offers New Views of Mouse Brain
New technology identified a rare population of astrocytes around blood vessels and hundreds of plaque-associated genes.
Can BACE Inhibitors Stage a Comeback?
At AAIC, and a separate BACE symposium, scientists argued the case for resuming evaluation of these drugs in clinical trials.
Neuropathologist Charles Duyckaerts Passes Away at Age 70
Stalwart of dementia neuropathology was best known for his work on tau pathology.
Alzheimer's Association International Conference (AAIC)- 2022
Crenezumab Secondaries Negative; Gantenerumab OLE Hints at Efficacy Can BACE Inhibitors Stage a Comeback? High-Res Spatial Transcriptomics Offers New Views of Mouse Brain Alzheimer's Blood Tests Have Arrived; Road to Broad Use Still Stretches On Bloo
Current Filters
- Date Range : All x